Title (en)

EPHA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF

Title (de)

EPHA2 AGONISTISCHE MONOKLONALE ANTIKÖRPER UND ANWENDUNGSVERFAHREN DAFÜR

Title (fr)

ANTICORPS MONOCLONAUX AGONISTIQUES EPHA2 ET PROCEDES D'UTILISATION CORRESPONDANTS

Publication

EP 1689346 A4 20071121 (EN)

Application

EP 04811773 A 20041119

Priority

- US 2004039112 W 20041119
- US 52417703 P 20031120

Abstract (en)

[origin: WO2005051307A2] The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to and agonize EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 levels in cells which EphA2 has been agonized. The invention also encompasses antibodies that preferentially bind an EphA2 epitope exposed on cancer cells but not non-cancer cells. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.

IPC 8 full level

A61K 39/395 (2006.01); **A61P 35/00** (2006.01); **C07H 21/04** (2006.01); **C07K 16/24** (2006.01); **C07K 16/28** (2006.01); **C07K 16/30** (2006.01); **C12N 5/20** (2006.01); **C12N 15/13** (2006.01); **C12N 15/63** (2006.01); **C12P 21/08** (2006.01)

IPC 8 main group level

A61K (2006.01)

CPC (source: EP KR)

A61K 39/395 (2013.01 - KR); **A61P 35/00** (2017.12 - EP); **A61P 35/04** (2017.12 - EP); **C07K 16/18** (2013.01 - KR); **C07K 16/24** (2013.01 - EP); **C07K 16/2866** (2013.01 - EP); **C07K 16/30** (2013.01 - EP KR); **C07K 16/3015** (2013.01 - EP); **C07K 16/3069** (2013.01 - EP); A61K 2039/505 (2013.01 - EP); C07K 2317/56 (2013.01 - EP); C07K 2317/565 (2013.01 - EP); C07K 2317/75 (2013.01 - EP)

Citation (search report)

- [PXL] WO 2004014292 A2 20040219 - PURDUE RESEARCH FOUNDATION [US], et al
- [X] WO 0112172 A1 20010222 - PURDUE RESEARCH FOUNDATION [US]
- [PX] US 2004091486 A1 20040513 - KINCH MICHAEL S [US], et al
- [PX] WO 03094859 A2 20031120 - MEDIMMUNE INC [US], et al
- [T] WO 2005056766 A2 20050623 - MEDIMMUNE INC [US], et al
- [T] LANDEN CHARLES N JR ET AL: "Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer", JNCI CANCER SPECTRUM, OXFORD UNIVERSITY PRESS, OXFORD, GB, vol. 98, no. 21, 1 November 2006 (2006-11-01), pages 1558 - 1570, XP002421774, ISSN: 1475-4029
- [PX] HU MIN ET AL: "EphA2 induction of fibronectin creates a permissive microenvironment for malignant cells.", MOLECULAR CANCER RESEARCH : MCR OCT 2004, vol. 2, no. 10, October 2004 (2004-10-01), pages 533 - 540, XP002435680, ISSN: 1541-7786
- [T] MILLER KATHY D ET AL: "EA5, novel EphA2-targeted monoclonal antibody, inhibits growth and metastasis in human breast cancer xenografts.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 46, no. Suppl. S, April 2005 (2005-04-01), & 96TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; ANAHEIM, CA, USA; APRIL 16 -20, 2005, pages 132, XP002435681, ISSN: 0197-016X
- [AA] HU MIN ET AL: "Antibody targeting of the EphA2 receptor tyrosine kinase on breast cancer cells.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 44, July 2003 (2003-07-01), & 94TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; WASHINGTON, DC, USA; JULY 11-14, 2003, pages 1234, XP008079516, ISSN: 0197-016X
- See references of WO 2005051307A2

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)

WO 2005051307 A2 20050609; **WO 2005051307 A3 20060908**; AU 2004293034 A1 20050609; AU 2004293034 B2 20120202; CA 2546763 A1 20050609; CN 1905899 A 20070131; CN 1905899 B 20110928; EP 1689346 A2 20060816; EP 1689346 A4 20071121; JP 2008500021 A 20080110; JP 4860477 B2 20120125; KR 20060135671 A 20061229

DOCDB simple family (application)

US 2004039112 W 20041119; AU 2004293034 A 20041119; CA 2546763 A 20041119; CN 200480040720 A 20041119; EP 04811773 A 20041119; JP 2006541599 A 20041119; KR 20067012152 A 20060619